A view from the Center


Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

‘Coop-etition’ could grow as medtech companies prepare for transformational innovation

by Glenn Snyder, Principal, MedTech Practice Leader, Deloitte Consulting LLP

I’ve been hearing the term “coop-etition” quite a bit recently as medical technology executives consider the impact outside organizations are beginning to have on their industry. There is an acknowledgement among many traditional device manufacturers that they might need to cooperate with consumer-centric/tech-savvy organizations as their world becomes more digital and increasingly consumer-focused.

Read more

STEP UP: When paired with gamification and a science-based engagement program, wearables can boost (and sustain) activity levels

by Greg Szwartz, Life Sciences data science practice lead, Deloitte Consulting LLP

At the Temple Mount in Jerusalem, the ancient construction is strikingly precise. Every stone in the outer wall appears to have been meticulously placed, and all of the stairs are exactly the same size and shape. The last flight of stairs leading to the entrance, however, is noticeably different. The width and height of the of the steps are erratic—some are narrow while others are broad.

Read more

Back to the future: With increased scrutiny over price increases, the fundamentals of organic growth in biopharma are more important than ever

by Cameron McClearn, principal, and Tom Yang, principal, Deloitte Consulting LLP

Price increases. This is arguably the most discussed topic in the biopharmaceutical industry today. In January, biopharmaceutical manufacturers raised list prices on more than 250 products.1 In July, 20 companies increased the list prices for more than 40 prescription drugs by an average of 13 percent.2 But are annual price increases a sustainable mechanism for driving future growth in biopharma?

Read more

Forging a new path to commercialization for cell and gene therapies

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma companies’ current technology systems.

Read more

Can our paper-based clinical-trial model make the jump to the virtual world?

by Dawn Anderson, Managing director, Deloitte Consulting LLP

I entered the pharmaceutical sector 32 years ago as a clinical research associate. In all that time, there has been surprisingly little change to the way biopharmaceutical companies and contract research organizations conduct clinical trials. While digital technology is widely available to the general population, it generally has not made its way into clinical trials.

Read more

Can the world’s biggest companies save health care?

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

It’s no secret that we often don’t get what we pay for when it comes to health care. While we spend upwards of $3.5 trillion a year for health care in the US1, our longevity, infant and child mortality, and maternal mortality fall behind other countries.2 Eric Topol, author of the book Deep Medicine,

Read more